Bharat Parenterals Ltd - 541096 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Bharat Parenterals Ltd made available the audio recording of its Q4 FY26 earnings conference call, which took place on May 19, 2026. Investors can access the recording to review the discussion on the company's operational and financial performance for the quarter and year ended March 31, 2026.
May 19 2026 17:05:00
Bharat Parenterals Ltd - 541096 - Corporate Action-Board approves Dividend
Bharat Parenterals board recommended a final dividend of ₹1.00 per equity share (10% on ₹10 face value) for FY26. Payout is within 30 days of AGM approval.
May 18 2026 17:05:00
Bharat Parenterals Ltd - 541096 - Board Meeting Outcome for Outcome Of Board Meeting
Bharat Parenterals announced FY26 cons. revenue increased 1.5% to ₹345.4 cr, while PAT loss narrowed by 37.5%. The board recommended a final dividend of ₹1.00 per share and re-appointed its cost and internal auditors.
May 18 2026 16:05:00
Bharat Parenterals Ltd - 541096 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Bharat Parenterals has scheduled an earnings conference call on May 19, 2026, at 3:00 PM IST. The call will discuss the company's operational and financial performance for Q4 and the full fiscal year 2026.
May 12 2026 09:05:00
Bharat Parenterals Ltd - 541096 - Board Meeting Intimation for Approving Audited Financial Results For The Quarter And Year Ended March 31, 2026 And Recommendation Of Final Dividend On Equity Shares.
Bharat Parenterals' Board of Directors will convene on May 18, 2026, to review and approve the audited financial results for Q4 & FY26. The board will also consider recommending a final dividend for the financial year.
May 09 2026 14:05:00
Bharat Parenterals Ltd - 541096 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Bharat Parenterals confirmed it does not meet the criteria to be identified as a Large Corporate as per SEBI circulars for fund raising through debt securities. This means the company is exempt from certain mandatory debt market participation requirements for Large Corporates.
Apr 29 2026 12:04:00
Bharat Parenterals Ltd - 541096 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Bharat Parenterals' subsidiary, Innoxel Lifesciences Pvt. Ltd., received 5 observations under Voluntary Action Indicated (VAI) from the U.S. FDA. The surprise inspection of its Vadodara finished dosage facility occurred from April 13-17 and April 20, 2026.
Apr 21 2026 13:04:00
Read More